Advances in Cancer Research - 1st Edition - ISBN: 9780123942807, 9780123978417

Advances in Cancer Research, Volume 113

1st Edition

Serial Editors: Paul Fisher Kenneth Tew
eBook ISBN: 9780123978417
Hardcover ISBN: 9780123942807
Imprint: Academic Press
Published Date: 30th March 2012
Page Count: 304
Tax/VAT will be calculated at check-out
101.00
172.68
166.00
126.00
Unavailable
File Compatibility per Device

PDF, EPUB, VSB (Vital Source):
PC, Apple Mac, iPhone, iPad, Android mobile devices.

Mobi:
Amazon Kindle eReader.

Institutional Access


Table of Contents

      1. The AID dilemma: infection, or cancer?
      2. Tasuku Honjo, Maki Kobayashi, Nasim Begum, Ai Kotani, Somayeh Sabouri, and Hitoshi Nagaoka

      3. The microRNA regulatory network in normal- and HTLV-1-transformed T cells
      4. Donna M. D’Agostino, Paola Zanovello, Toshiki Watanabe and Vincenzo Climinale

      5. The multifaceted oncoprotein Tax: Sub-cellular localization, post-translational modifications and NF-κB activation
      6. Youmna Kfoury, Rihab Nasr, Chloé Journo, Renaud Mahieux, Claudine Pique and Ali Bazarbachi

      7. Lynch or not Lynch? Is that always a question?
      8. Chrystelle Colas, Florence Coulet, Magali Svrcek, Ada Collura, Jean-François Fléjou, Alex Duval and Richard Hamelin

      9. Activation induced deaminase in antibody diversification and chromosome translocation
      10. Anna Gazumyan, Anne Bothmer, Isaac A. Klein, Michel C Nussenzweig and Kevin M. McBride

      11. Opportunities and challenges in tumor angiogenesis research: back and forth between bench and bed
      12. Li Qin, Jennifer L. Bromberg-White, and Chao-Nan Qian

      13. Molecular Logic Underlying Chromosomal Translocations, Random or non-Random?

      Chunru Lin, Liuqing Yang and Michael G. Rosenfeld

 


Description

Advances in Cancer Research provides invaluable information on the exciting and fast-moving field of cancer research. Here, once again, outstanding and original reviews are presented on a variety of topics.

Key Features

  • 113th volume of Advances in Cancer Research
  • Expert authors
  • Chapters on topics including microRNA regulatory network, multifaceted oncoprotein tax, and underlying chromosomal translocations

Readership

Researchers and students in the basic and clinical sciences of cancer biology and oncology, plus related areas in genetics, immunology, pharmacology, cell biology, and molecular biology.


Details

No. of pages:
304
Language:
English
Copyright:
© Academic Press 2012
Published:
Imprint:
Academic Press
eBook ISBN:
9780123978417
Hardcover ISBN:
9780123942807

Reviews

Praise for the Serial
"This classic and essential series presents critical overviews on select aspects of both cancer research and the basic underlying sciences." --American Scientist
"Excellent, highly informative, in-depth reviews…expertly written, up-to-date, and well-referenced." --Journal of Medicinal Chemistry
"This is a series that has a long tradition of excellence in the field of cancer biology." --Doody’s Publishing Reviews


About the Serial Editors

Paul Fisher Serial Editor

Kenneth Tew Serial Editor

Professor & Chairman, Dept of Cell & Molecular Pharmacology John C. West Chair of Cancer Research, Medical University of South Carolina, USA

The Tew laboratory maintains an interest in using redox pathways as a platform to develop therapeutic strategies through drug discovery/development and biomarker identification. We interrogate how reactive oxygen and nitrogen species (ROS/RNS) impact cancer cells and develop novel drugs that impact on glutathione based pathways. Our research efforts have been integral to studies that have identified glutathione S-transferases (GST) as important in drug resistance, catalytic detoxification and as arbiters of kinase-mediated cell signaling events. In addition, we have been instrumental in defining how GSTP contributes to the process by which cells respond to ROS by selective addition of glutathione to specific protein clusters, so called S-glutathionylation. Each of these research areas has had broad impact on a number of cancer disciplines. Moreover, we have also been seminally involved in the Phase I to III clinical testing of three oncology drugs, Telcyta, Telintra and NOV-002. Other ongoing translational efforts have produced two ongoing clinical trials to measure the effectiveness of serum S-glutathionylated serine proteinase inhibitors as possible biomarkers for exposure to hydrogen peroxide mouthwashes and radiation.

Affiliations and Expertise

Department of Cell and Molecular Pharmacology, Medical University of South Carolina, USA